CLDN18.2-Specific CAR T-Cell Therapy Prolongs PFS in Patients with Previously Treated Advanced Gastric or Gastro-oesophageal Junction Cancer By Ogkologos - August 14, 2025 753 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the CT041-ST-01 study Source RELATED ARTICLESMORE FROM AUTHOR Giredestrant plus everolimus prolongs PFS among patients with ER-positive, HER2-negative, ESR1-mutated advanced breast cancer after the receipt of a CDK4/6 inhibitor EMA Recommends Granting a Marketing Authorisation for Ensartinib Taking on the RAS Challenge MOST POPULAR Molecular Analysis for Precision Oncology Congress 2024 London, UK, 16-18 October October 14, 2024 Recognising the essential role of clinical research nurses October 13, 2021 Targeted Therapy for Treating Advanced Gastrointestinal Stromal Tumors (GISTs): The ASCO... January 24, 2022 Some Brain Cells May Help to Fuel Cancer Metastasis November 21, 2019 Load more HOT NEWS Study Shows that Disrupted Gut Bacteria May Contribute to the Spread... Cancer Research UK honours Her Majesty The Queen, the charity’s Patron EMA Adopts a New Pharmaceutical Form of Selumetinib EMA Recommends Extension of Indications for Lorlatinib
